By

Lundbeckfonden
Cambridge, UK and Indianapolis, US – 15 October 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”) provides an update following receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in respect of its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) on 5 October 2018. “Our discussions...
FDA issued a Complete Response letter to Acacia Pharma on Friday 5 October Only issue raised relates to FDA inspection of contract manufacturer of active ingredient No other quality or manufacturing deficiencies noted No clinical safety or efficacy issues identified and no requirement for further clinical studies or data analyses Conference call scheduled for 09.30...
Lund, Sweden, 08:00 CET, 08 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces that its US commercial team will be showcasing CERAMENT®|BONE VOID FILLER (CERAMENT®|BVF) at two important US orthopedic conferences taking place in October. These marketing activities are taking place just ahead of the launch...
New method paves the way for mass production of snake antivenom without the many side effects of today’s products. Danish scientists – including a recipient of the Lundbeck Foundation Talent Prize – played an important role in the research and development. Every year, around 100,000 people worldwide die from snakebites, and at least 400,000 of...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
Pruritus Relief thru Itch-Scratch Modulation (PRISM) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic and other serious neurological conditions, today announced initiation of a pivotal clinical trial evaluating Nalbuphine ER in patients...
All set to evaluate the most prominent brain-related ventures. Six leading researchers will be the critical quality filter that will help the Lundbeck Foundation realise its ambition to make Denmark a world leader in brain research. These six scientists will make up a new Grants & Prizes Panel whose job, among other things, is to assist...
Lund, Sweden, 18:00 CET 28 September 2018 – During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 September 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,555,917. For more information contact: BONESUPPORT AB Emil...
Scientists at the University of Copenhagen have received grants totalling 90 million Danish kroner to fund different ways of studying the hologenome – the collaboration between an animal’s own DNA and its gut bacteria. Salmon and fieldmice play a key role in this major research project, devoted to both the environment and development of new...
Lund, Sweden, 08:00 CET, 19 September 2018 – Strategic review has led to important initiatives to strengthen BONESUPPORT’s US and European commercial platforms Excellent progress in creating own distributor network in the US. 18 new distributors contracted. 425 highly motivated sales reps to sell BONESUPPORT’s products from 21 October 2018   European commercial expansion on track...
1 2 3 13

News

Poisonous snakes: Scientists identify clever antivenom cocktail
2. October 2018
Lundbeck Foundation appoints a Grants & Prizes Panel
1. October 2018
Salmon and fieldmice to shed light on the enigmatic hologenome
28. September 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge